<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Patients with primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp> (PSC) and <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) have a high risk of developing <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="1" ids="9907">Ursodeoxycholic acid</z:chebi> (UDCA) has been suggested to have chemopreventive effects on the development of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and <z:mpath ids='MPATH_589'>dysplasia</z:mpath> but long-term data and larger trials are lacking </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: To evaluate the effect of high dose (17-23��mg/kg/day) UDCA on colorectal <z:hpo ids='HP_0002664'>neoplasia</z:hpo> in a cohort of patients with PSC and IBD </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: From our previous 5-year randomised controlled trial of UDCA vs. placebo in PSC, we performed a follow-up of 98 patients with concomitant IBD from entry of the trial 1996-1997 until 2009 for development of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> or <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The total follow-up time was 760 person-years </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_589'>Dysplasia</z:mpath>/<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-free survival was compared between placebo- (n = 50) and UDCA-treated (n = 48) patients </plain></SENT>
<SENT sid="6" pm="."><plain>There was a similar frequency of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> after 5 years between patients originally assigned to UDCA or placebo (13% vs. 16%) and no difference in <z:mpath ids='MPATH_589'>dysplasia</z:mpath>/<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-free survival (P = 0.46, log rank test) </plain></SENT>
<SENT sid="7" pm="."><plain>At the end of 2009 no difference in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-free survival was detected, 30% of the placebo patients compared with 27% of UDCA patients had developed <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> or <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Long-term high dose <z:chebi fb="1" ids="9907">ursodeoxycholic acid</z:chebi> does not prevent <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> or <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in patients with primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp>-associated <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> </plain></SENT>
</text></document>